Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback